Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US-10253018-B2 · Apr 9, 2019 · US
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11345699-B2 |
| Application number | US-201916688429-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2019 |
| Priority date | Nov 19, 2018 |
| Publication date | May 31, 2022 |
| Grant date | May 31, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
First claim
Opening claim text (preview).
What is claimed: 1. A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof: Compound Structure 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11345699B2 cover?
- The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions compr…
- Who is the assignee on this patent?
- Enanta Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).